Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Nibedita Bandyopadhyay"'
Autor:
Julie R. Brahmer, MD, Melissa L. Johnson, MD, Manuel Cobo, MD, PhD, Santiago Viteri, MD, Juan Coves Sarto, MD, Ammar Sukari, MD, Mark M. Awad, MD, PhD, Ravi Salgia, MD, PhD, Vali A. Papadimitrakopoulou, MD, Arun Rajan, MD, Nibedita Bandyopadhyay, PhD, Alicia J. Allred, PhD, Mark Wade, MA, Gary E. Mason, MD, Enrique Zudaire, PhD, Roland E. Knoblauch, MD, PhD, Nicole Stone, PhD, Matthew V. Lorenzi, PhD, Raffit Hassan, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100103- (2021)
Introduction: JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted Listeria monocytogenes–based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phase 1) and in combination wit
Externí odkaz:
https://doaj.org/article/bbb4d20374c844f282e02141b37f3640
Autor:
Emerson A. Lim, Michael T. Schweizer, Kim N. Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron R. Hansen
Publikováno v:
Clinical Genitourinary Cancer. 21:366-375
Autor:
Enriqueta Felip, Victor Moreno, Daniel Morgensztern, Giuseppe Curigliano, Piotr Rutkowski, José Manuel Trigo, Aitana Calvo, Dariusz Kowalski, Diego Cortinovis, Ruth Plummer, Michele Maio, Paolo A. Ascierto, Vladimir I. Vladimirov, Andres Cervantes, Enrique Zudaire, Anasuya Hazra, Huybrecht T’jollyn, Nibedita Bandyopadhyay, James G. Greger, Edward Attiyeh, Hong Xie, Emiliano Calvo
Publikováno v:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
Purpose To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the
Autor:
Roland Elmar Knoblauch, Sumit K. Subudhi, Dirk G. Brockstedt, Suzette Girgis, Enrique Zudaire, Nibedita Bandyopadhyay, Mark Wade, Jeffrey R. Infante, Russell K. Pachynski, Dolly A. Parasrampuria, Douglas G. McNeel, Nicole L. Stone, Charles G. Drake, Peter Lauer, Lawrence Fong, Gary Mason, Daniel Patricia, Todd M. Bauer, Emmanuel S. Antonarakis, Marco Gottardis
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:219-228
Background The safety and immunogenicity of JNJ-64041809 (JNJ-809), a live-attenuated, double-deleted Listeria monocytogenes (LADD Lm)-based immunotherapy targeting 4 relevant prostate cancer antigens, was evaluated in a phase 1 study in patients wit
Autor:
Dingwei Ye, Katherine B. Bevans, Andrea J. Pereira de Santana Gomes, Sabine Brookman-May, Byung Ha Chung, Simon Chowdhury, Suneel Mundle, Álvaro Juárez, Ke Zhang, Kim N. Chi, Mustafa Ozguroglu, Anders Bjartell, Sharon Anne McCarthy, Julie S. Larsen, Neeraj Agarwal, Weili Sun, Robert Given, Nibedita Bandyopadhyay, Hirotsugu Uemura, Axel S. Merseburger
Publikováno v:
Journal of Clinical Oncology. 39:2294-2303
PURPOSE The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sen
Autor:
Judy Wang, Patricia Martin-Romano, Philippe Cassier, Melissa Johnson, Eric Haura, Laurie Lenox, Yue Guo, Nibedita Bandyopadhyay, Michael Russell, Elizabeth Shearin, Josh Lauring, Laetitia Dahan
Publikováno v:
The oncologist. 27(7)
Background Patients with KRAS-mutant cancers have limited treatment options. Here we present a phase I study of JNJ-74699157, an oral, selective, covalent inhibitor of the KRAS G12C isoform, in patients with advanced cancer harboring the KRAS G12C mu
Autor:
Torben Plesner, Philippe Moreau, Ivo Nnane, Andrew Farnsworth, Peter Hellemans, Nibedita Bandyopadhyay, Maria-Victoria Mateos, Albert Oriol, Saad Z. Usmani, Hareth Nahi, Donna Zemlickis, Ajai Chari, Brenda Tromp, Niels W.C.J. van de Donk
Publikováno v:
Nahi, H, Usmani, S Z, Mateos, M-V, van de Donk, N W C J, Moreau, P, Oriol, A, Plesner, T, Bandyopadhyay, N, Hellemans, P, Tromp, B, Nnane, I, Zemlickis, D, Farnsworth, A & Chari, A 2021, ' Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study ', Blood, vol. 138, no. Suppl. 1, 1667 . https://doi.org/10.1182/blood-2021-148990
Introduction: Daratumumab (DARA) is a human monoclonal IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. DARA is approved as monotherapy or in combination with standard-of-care regimens for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcc75dc285d56f1f5d692605266dfcd
https://portal.findresearcher.sdu.dk/da/publications/802018b7-d210-456f-8fd7-acf3330c9b9a
https://portal.findresearcher.sdu.dk/da/publications/802018b7-d210-456f-8fd7-acf3330c9b9a
Autor:
Laura E. Hogan, Teena Bhatla, David T. Teachey, Francisco José Bautista Sirvent, John Moppett, Pablo Velasco Puyó, Concetta Micalizzi, Claudia R?Ssig, Neerav Shukla, Gil Gilad, Franco Locatelli, Andre Baruchel, C. Michel Zwaan, Elizabeth A. Raetz, Nibedita Bandyopadhyay, Lorena Lopez Solano, Robyn Monet Dennis, Robin L. Carson, Ajay Vora
Publikováno v:
Journal of Clinical Oncology. 40:10001-10001
10001 Background: Approximately 15-20% of pediatric pts with ALL or LL will be refractory to/relapse after frontline treatment; relapsed disease is associated with poor outcomes. In a phase 2 study, 2 of 7 (28.6%) pts with T-cell ALL in first relapse
Autor:
Emerson A. Lim, Michael Thomas Schweizer, Kim N. Chi, Rahul Raj Aggarwal, Neeraj Agarwal, James L. Gulley, Edward F. Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron Richard Hansen
Publikováno v:
Journal of Clinical Oncology. 40:279-279
279 Background: PSMA expression is increased in response to anti-androgen therapies and is a promising therapeutic target for the treatment of prostate cancer (PCa). JNJ-081 is a bispecific antibody with one arm binding PSMA on cancer cells and the o
Autor:
Charles G, Drake, Russell K, Pachynski, Sumit K, Subudhi, Douglas G, McNeel, Emmanuel S, Antonarakis, Todd M, Bauer, Peter, Lauer, Dirk, Brockstedt, Daniel, Patricia, Mark, Wade, Enrique, Zudaire, Nibedita, Bandyopadhyay, Dolly A, Parasrampuria, Suzette, Girgis, Gary E, Mason, Roland E, Knoblauch, Nicole, Stone, Jeffrey R, Infante, Marco M, Gottardis, Lawrence, Fong
Publikováno v:
Prostate cancer and prostatic diseases. 25(2)
The safety and immunogenicity of JNJ-64041809 (JNJ-809), a live-attenuated, double-deleted Listeria monocytogenes (LADD Lm)-based immunotherapy targeting 4 relevant prostate cancer antigens, was evaluated in a phase 1 study in patients with metastati